Syphilis | Appendix B: Panel Roster and Financial Disclosures | Adult and Adolescent Opportunistic Infection | ClinicalInfo

Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

Updated

Aug. 01, 2019

Reviewed

Aug. 01, 2019

Appendix B: Panel Roster and Financial Disclosures

Syphilis

Syphilis
Member		Financial Disclosure
Member		Company	Relationship
Bolan, Gail	Centers for Disease Control and Prevention	None	N/A
Ghanem, Khalil	Johns Hopkins University	None	N/A
Hollier, Lisa	Baylor College of Medicine	None	N/A
Hook, Edward W.	University of Alabama at Birmingham	National Institutes of Health	Research Support
Sena, Arlene	University of North Carolina	Gilead Sciences	Research Support
		GlaxoSmithKline	Research Support
		Hologic, Inc	Speaking Compensation, Advisory Board
		Lupin Pharmaceuticals, Inc	Research Support
		UpToDate	Royalties
Stoner, Brad	Washington University School of Medicine	None	N/A
Workowski, Kim*	Emory University	Acuris	Research Support
		Gilead Sciences	Advisory Board, Research Support
		GlaxoSmithKline	Advisory Board, Research Support
		Janssen Pharmaceuticals	Advisory Board
* Group lead Note: Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.

Download Guidelines

Section OnlyPDF (507.01 KB)
Full GuidelinePDF (3.78 MB)
Tables OnlyPDF (481.21 KB)